TranS1 Inc. has received the CE Mark approval to market its VEO lateral access fusion system in Europe. The system is designed for use in interbody fusions, where two vertebra are fused together to treat pain or spinal deformities such as scoliosis. The device is appropriate for skeletally mature patients with degenerative disc disease who have had non-operative treatment for at least 6 months.
“We are very pleased to receive the CE Mark for the VEO lateral system,” said Ken Reali, president and CEO of TranS1. “We are excited to begin executing on our commercialization strategy in Europe as we enter the third quarter.”
The VEO system is minimally invasive, and it features a two-stage muscle retraction method that first visualizes nerves and then retracts the muscle. VEO also visualizes the psoas muscle, the muscle descending from the side of the lumbar region of the vertebral column to the brim of the lesser pelvis, and adjacent nerves before dissection. According to the TranS1, this allows the augmentation of neuromonitoring information and helps the surgeon avoid nerves while dissecting the muscle to get to the operative site.
VEO can be paired with a range of polyetheretherketone—or PEEK—lateral interbody implants and ergonomic instruments. The implants have radiopaque markers inside them to allow correct placement.
TranS1 is based in Wilmington, N.C., and develops medical devices for the treatment of degenerative conditions of the lumbar region of the spine.